The Complete DeKalb County Guide to Rick Simpson Oil (RSO): Understanding Traditional RSO, Modern Formulations, and Legal Access in Northeast Indiana

If you’re reading this from Auburn, Butler, Garrett, or anywhere else across DeKalb County’s 365 square miles of rich farmland and tight-knit communities, you’ve probably heard whispers about Rick Simpson Oil. Maybe you caught a conversation at the DeKalb County Fair about cannabis extracts for chronic pain. Perhaps someone mentioned it while waiting in line at the Parkview DeKalb Health emergency room. Or you’re sitting in your kitchen in Waterloo, searching online after a doctor told you there were no more options for your condition. Wherever you are in DeKalb County, this guide is for you.

We created this comprehensive resource because we know the challenges our neighbors face here in Northeast Indiana. When you’re dealing with cancer, chronic pain that makes it hard to work the fields, PTSD from military service, or the desperation that comes after prescription medications fail, you need honest information—not hype. You need to understand what RSO actually is, what the science says, and how you can access legal, tested products without leaving DeKalb County or risking legal trouble. This is everything we wish we’d known when we started, written specifically for the people of DeKalb County.

ABOUT RICK SIMPSON AND TRADITIONAL RICK SIMPSON OIL

Who is Rick Simpson

Rick Simpson was born in 1949 in Amherst, Nova Scotia, Canada. He was not a doctor, scientist, or medical professional—he was a power engineer and maintenance worker, a blue-collar tradesman whose path into cannabis advocacy began not with research but with personal suffering and a deep distrust of the medical system that failed him. We mention this because we know many folks in DeKalb County are skeptical of medical institutions too—maybe you’ve experienced long wait times at DeKalb Health, or felt your concerns were dismissed at a specialist’s office in Fort Wayne. Simpson’s story resonates because it’s about someone who got hurt, didn’t get answers, and found his own way forward.

In 1997, while working at a hospital in Moncton, New Brunswick, Simpson fell from scaffolding and suffered a serious head injury. The aftermath included persistent tinnitus, dizziness, and a constellation of post-concussion symptoms that conventional medicine could not adequately resolve. According to Simpson, the medications he was prescribed either failed to help or made his condition worse. He reported that cannabis provided more relief than anything his doctors offered, but when he asked his physician to support or prescribe cannabis, the request was refused .

Simpson’s interest in concentrated cannabis oil deepened after he learned about a 1974 study funded by the National Institute of Health and conducted at the Medical College of Virginia, in which THC was reported to slow or shrink tumors in mice. That study—originally intended to demonstrate harm—became a foundational reference point in Simpson’s later advocacy, even though its findings were never replicated in controlled human cancer trials .

The pivotal moment in Simpson’s story came in 2003. He reported that three bumps on his arm were diagnosed by his doctor as basal cell carcinoma. Rather than pursuing conventional treatment, Simpson applied concentrated cannabis oil directly to the lesions, covered them with bandages, and waited. According to his account, the bumps disappeared within four days. No independent medical verification of this outcome has been published, and no biopsy confirmation or clinical follow-up has been documented in any peer-reviewed source. Nevertheless, this personal experience became the origin story of Rick Simpson Oil and the foundation of everything that followed .

Important context: Simpson’s account is presented here as his personal testimony. The absence of clinical documentation, controlled observation, or independent medical confirmation means these events cannot be evaluated as medical evidence. They are, however, historically significant as the catalyst for a global movement around concentrated cannabis oil. For DeKalb County readers facing serious health challenges, we share this story not as medical proof, but as the historical context that explains why millions worldwide began seeking cannabis oil.

The crusade—spreading the oil

After his 2003 experience, Simpson committed himself fully to producing and distributing concentrated cannabis oil. Operating out of his property in Maccan, Nova Scotia, he began making the oil in large quantities and giving it away for free to cancer patients and others in his community. He charged nothing. By his own account, he helped dozens of people with conditions including cancer, chronic pain, diabetes, infections, glaucoma, arthritis, depression, insomnia, and more .

Simpson’s story reached a global audience through the 2005 documentary Run From The Cure, directed by Christian Laurette. The film documented Simpson’s claims, showed testimonials from people he had treated, and framed his work as a grassroots challenge to pharmaceutical and governmental interests. It was distributed freely online and became one of the most widely shared cannabis advocacy films of its era. Within cannabis communities, it was foundational—for many people, Run From The Cure was their introduction to the concept of concentrated cannabis oil as medicine .

Simpson’s advocacy brought him into direct conflict with Canadian law. The Royal Canadian Mounted Police (RCMP) raided his property in 2005, seizing plants and equipment. He was charged with cannabis cultivation, possession, and trafficking. Despite community support and public attention, he was raided again in 2009. He was acquitted on some charges but convicted on others. Facing continued legal pressure, Simpson eventually left Canada and relocated to Europe, living in Croatia and later the Netherlands, where he continued his advocacy from abroad .

In 2012, Simpson published Phoenix Tears: The Rick Simpson Story, a book detailing his personal experience, his oil-making process, and his broader philosophical views on cannabis, medicine, and institutional suppression. He also maintained phoenixtears.ca as his primary online platform for information and advocacy .

Throughout his public career, Simpson’s position remained consistent and uncompromising: he maintained that cannabis oil—particularly high-THC oil made according to his specific method—could cure cancer and many other diseases, and that pharmaceutical companies, government agencies, and medical institutions were actively suppressing this knowledge to protect their financial interests. He framed his work not merely as health advocacy but as a fight against institutional corruption .

Important context: Simpson’s conspiratorial framing is noted here without endorsement or dismissal. It reflects a worldview shared by many in the early cannabis movement and is relevant to understanding why RSO became culturally significant. For DeKalb County readers who may have experienced healthcare frustrations or pharmaceutical costs that feel insurmountable, we acknowledge that skepticism toward institutions is understandable. Our approach is different: we’re transparent about what we know and what we don’t.

The traditional RSO protocol—Simpson’s 60-gram, 90-day regimen

Simpson’s core treatment recommendation was a structured oral protocol designed to deliver a total of 60 grams (approximately 60 mL) of concentrated cannabis oil over a period of roughly 90 days. He described this as a cancer treatment protocol, though he also recommended it for numerous other conditions. The following is a detailed breakdown of the protocol as Simpson described it .

Goal

Consume 60 grams of concentrated, high-THC cannabis oil over approximately 90 days. Simpson considered this the minimum amount necessary for a serious cancer treatment course.

Titration schedule

• Week 1: Begin with a dose approximately the size of half a grain of dry rice—roughly 10 to 15 milligrams of oil—taken three times per day (morning, afternoon, and before bed). Total daily intake during this phase: approximately 30 to 45 milligrams. Simpson emphasized that the initial doses should be very small to allow the body to begin adjusting to the psychoactive effects of THC.

• Weeks 2 through 5: Double the dose approximately every four days. The purpose of the slow ramp-up was to build THC tolerance gradually and minimize disruption from the psychoactive effects. By the end of this escalation period—roughly four to five weeks in—the target was to reach approximately 1 gram (1,000 milligrams) of oil per day, divided into three roughly equal doses.

• Weeks 5 through 12: Maintain the full dose of approximately 1 gram per day, divided into three doses of roughly 333 milligrams each, and continue until the full 60 grams have been consumed. At this dosing level, the remaining 50-plus grams of oil would be consumed over the final seven to eight weeks.

Administration methods

• Primary method—oral: Simpson recommended placing the dose directly under the tongue (sublingual) or swallowing it. He considered oral ingestion the most important route for systemic absorption and the primary method for internal cancers and other systemic conditions.
• Secondary method—topical: For skin cancers and external lesions, Simpson recommended applying the oil directly to the affected area, covering it with a bandage, and changing the bandage every three to four days. He combined topical application with oral dosing for skin cancers.
• Not recommended as primary—inhalation: Simpson did not recommend smoking or vaporizing the oil as a primary treatment method. He acknowledged inhalation for immediate symptom relief (pain, nausea) but maintained that the oral route was necessary for the sustained, high-dose exposure he considered therapeutically essential.

Tolerance and the psychoactive effects

• Simpson maintained that patients would develop significant tolerance to the psychoactive effects of THC within approximately three to four weeks of consistent dosing at escalating levels.
• He considered the euphoric, sedating, or disorienting effects a minor and temporary side effect and strongly urged patients not to let the high discourage them from continuing the protocol.
• He recommended that patients take their initial doses at night or before bed to sleep through the most intense psychoactive effects during the early titration phase.
• Simpson also recommended that patients avoid driving or operating machinery during the titration period and that they inform family members about what to expect.

Post-protocol maintenance

• After completing the full 60-gram course, Simpson recommended a maintenance dose of approximately 1 to 2 grams of oil per month, taken indefinitely.
• He considered this ongoing low-dose maintenance important for long-term health and cancer prevention.
• Simpson indicated that maintenance dosing was much lower than the treatment dose and that patients who had completed the full protocol would have sufficient THC tolerance to handle it comfortably.

Dietary and lifestyle recommendations

• Simpson also advocated for dietary changes alongside the oil protocol, including reducing sugar intake, avoiding processed foods, and improving overall nutrition.
• He was not specific or systematic about dietary protocols compared to his highly detailed oil protocol—dietary advice was secondary and general.

Important context for evaluating this protocol

This protocol was designed by one person based on his personal experience and anecdotal observations. It was not developed through clinical trials, dose-finding studies, pharmacokinetic modeling, or any formal research process. Several critical points apply:

• No controlled trial validation. There are no published randomized controlled trials, cohort studies, or even well-documented case series evaluating this specific 60-gram/90-day protocol for any cancer type or any other condition.
• Assumes crude, unstandardized material. The 60-gram quantity assumes a single-strain, THC-dominant extract with no standardized potency. Actual THC content per gram of traditional RSO varied widely depending on the starting plant material and extraction technique.
• Very high THC exposure. At the peak dosing phase, patients were consuming roughly 1 gram of high-THC oil per day. Assuming traditional RSO contained 60 to 90 percent THC, this translates to approximately 600 to 900 milligrams of delta-9 THC per day—a dose far exceeding anything studied in controlled clinical settings. For context, the FDA-approved synthetic THC drug dronabinol is typically dosed at 2.5 to 20 milligrams per day.
• Real risks at these doses. Consuming 600 to 900 milligrams of THC daily carries serious risks including severe intoxication, impairment, anxiety, panic, tachycardia, hypotension, and cannabis use disorder. These risks are well-documented in the GENERAL KNOWLEDGE section of this document [1][13][14][15].
• Oncology context. Patients with active cancer are often medically complex. Using unregulated, unstandardized cannabis oil as a primary cancer treatment—potentially in place of proven therapies—introduces harm that extends beyond the oil itself.

For DeKalb County residents considering RSO for serious conditions, we cannot emphasize this enough: this protocol has never been clinically validated. If you’re receiving treatment at Parkview Cancer Institute in Fort Wayne or DeKalb Health in Auburn, please discuss any cannabis use with your oncologist before making decisions that could affect your care.

What is traditional Rick Simpson Oil—the product

Traditional RSO refers to the specific type of concentrated cannabis oil that Simpson made and advocated for. It was defined not by lab specifications or regulatory standards but by his method and materials. The following describes the product as Simpson produced it .

Source material

Simpson used high-THC, indica-dominant cannabis strains. He specifically favored heavy, sedating indica genetics and generally recommended against sativa-dominant strains for cancer treatment, believing that indica strains produced better therapeutic outcomes. He grew his own cannabis or sourced it from growers he trusted. There was no strain standardization—the starting material varied by availability and growing season. For DeKalb County readers who might see “indica” or “sativa” on products in Michigan dispensaries (the nearest legal market), this explains why Simpson had such a strong preference.

Extraction solvent

Simpson originally used naphtha—a petroleum-based solvent commercially available as lighter fluid, Varsol, or similar products. He later also endorsed 99 percent isopropyl alcohol as an acceptable alternative. He explicitly warned against using other solvents, including butane or acetone, due to safety and purity concerns. Neither naphtha nor isopropyl alcohol is a food-grade solvent, which is a significant safety issue discussed further below.

Extraction process

1. Dry or semi-dry cannabis plant material was placed in a container (typically a bucket).
2. The material was covered with solvent and agitated or stirred for several minutes to dissolve cannabinoids and other fat-soluble compounds from the plant.
3. The solvent was poured off through a filter, typically cheesecloth or a similar mesh material, into a separate collection vessel.
4. The process was repeated a second time with fresh solvent on the same plant material to extract remaining cannabinoids.
5. The combined solvent washes—now a dark, cannabinoid-rich liquid—were placed in a rice cooker or similar open-vessel heating device.
6. The solvent was evaporated at relatively low heat. Simpson recommended a rice cooker specifically because it maintains a temperature range that evaporates the solvent without exceeding the point at which cannabinoids degrade significantly. However, this temperature was still high enough to decarboxylate THCa into THC and to destroy most volatile terpenes.
7. As the solvent evaporated, a thick, dark oil remained at the bottom of the vessel.
8. The final oil was transferred into oral syringes for storage and dosing.

Appearance and physical characteristics

Traditional RSO was an extremely dark—nearly black—thick, viscous, tar-like oil. It had a strong cannabis odor and could carry a faint solvent-residual smell depending on how thoroughly the solvent was purged. The consistency was sticky and difficult to handle at room temperature but became more fluid when warmed slightly.

Cannabinoid profile

• Primarily decarboxylated delta-9 THC. The heat involved in solvent evaporation converted essentially all THCa in the extract into delta-9 THC. Traditional RSO was therefore an activated, THC-dominant product.
• Naturally occurring minor cannabinoids. Whatever CBD, CBN, CBC, CBG, and other minor cannabinoids the source strain contained were present at their natural ratios, but these were not controlled, measured, or targeted.
• No ratio control. There was no ability to adjust or standardize specific cannabinoid ratios. The profile was entirely determined by the genetics and growing conditions of the source plant.
• Estimated THC content. Depending on starting material, traditional RSO likely ranged from approximately 60 to 90 percent total THC by weight, though this was never lab-verified in the traditional production context.

Terpene content

Minimal to none. The combination of solvent extraction (which dissolves terpenes into the solvent along with cannabinoids) and the subsequent high-heat evaporation process (which volatilizes terpenes at temperatures well below cannabinoid degradation thresholds) meant that traditional RSO was effectively stripped of its terpene content. This is a significant distinction from modern formulations that deliberately preserve or reintroduce terpenes.

Standardization and testing

None. Every batch of traditional RSO was different because it depended entirely on the starting plant material, growing conditions, solvent purity, extraction technique, evaporation temperature and duration, and the individual maker’s process. Simpson operated before cannabis legalization and the standardized lab-testing infrastructure that came with it. There was no Certificate of Analysis, no cannabinoid quantification, and no contaminant screening.

Residual solvent risk

This is one of the most significant safety concerns with traditional RSO production. Naphtha and isopropyl alcohol are not food-grade solvents. Naphtha in particular is a complex mixture of petroleum hydrocarbons that may contain benzene, toluene, xylene, and other compounds with established toxicity. Incomplete solvent purging—which is very difficult to verify without analytical chemistry equipment—leaves potentially harmful residues in the finished oil.

Modern cannabis extraction overwhelmingly uses food-grade ethanol or supercritical carbon dioxide (CO₂). These methods allow for much more complete solvent removal, and the finished products can be tested for residual solvents using validated analytical methods such as headspace gas chromatography. This is one of the most straightforward improvements that the modern regulated cannabis industry has made over the traditional RSO production model.

For DeKalb County residents who might know someone attempting to make RSO at home in a rural workshop or kitchen, this safety information is critical. The risks of naphtha exposure, fire hazards, and residual contamination are real and potentially life-threatening.

Simpson’s claims vs. the evidence record

Rick Simpson made expansive therapeutic claims about his oil. He stated that RSO could cure cancer—including terminal cases—and that it was effective against diabetes, chronic pain, infections, glaucoma, arthritis, depression, insomnia, multiple sclerosis, and numerous other conditions. He was adamant, consistent, and public about these claims throughout his advocacy career .

It is important to evaluate these claims against the actual evidence base, using the same standards applied throughout this document.

What Simpson was not

Simpson was not a scientist, physician, pharmacologist, or researcher. He had no formal training in medicine, oncology, pharmacology, or clinical research methodology. He never designed, conducted, funded, or published a clinical trial. He never submitted his results to peer review. His entire evidence base consisted of personal experience, self-reported patient outcomes, and testimonials gathered informally—with no controls, no independent verification, no imaging confirmation, no long-term follow-up, and no blinding.

What the preclinical literature shows

The preclinical cannabinoid-cancer literature does exist, and it is scientifically interesting:

• In vitro studies have demonstrated that THC and CBD can induce apoptosis (programmed cell death), inhibit proliferation, and reduce angiogenesis (blood vessel formation that feeds tumors) in certain cancer cell lines .
• Animal model studies have shown some tumor-growth inhibition in mice and rats treated with cannabinoids .
• These findings have generated legitimate scientific interest and ongoing research.

What the preclinical literature does not show

• These findings have not translated into proven human cancer cures. The gap between in vitro or animal results and human clinical outcomes is vast, well-documented across all of oncology research, and especially relevant here.
• No human clinical trial has demonstrated that RSO or any cannabis oil preparation cures cancer.
• Several small human trials of cannabinoids in cancer contexts (particularly glioblastoma) have been conducted, but they have been exploratory, small, and have not produced the kind of results that would support cancer-cure claims .

Institutional positions

• The U.S. National Cancer Institute (NCI) acknowledges that cannabinoids have been studied for potential anticancer effects in laboratory and animal models but does not endorse cannabis or cannabis oil as a cancer treatment .
• The U.S. Food and Drug Administration (FDA) has not approved any cannabis plant product for the treatment of cancer. The only FDA-approved cannabinoid-related products are for other specific indications: Epidiolex (CBD) for certain seizure disorders and dronabinol/nabilone (synthetic THC analogues) for chemotherapy-related nausea and AIDS-related wasting [1].
• Health Canada has never approved RSO or cannabis oil as a cancer cure.
• NCCIH explicitly states that the strongest cannabinoid evidence is for rare epilepsies, chemotherapy-related nausea and vomiting, and appetite-related indications in HIV/AIDS—not cancer cure [1].

For DeKalb County residents receiving treatment at major cancer centers like Parkview Cancer Institute in Fort Wayne or even traveling to IU Health in Indianapolis, these institutional positions matter. These are the standards your oncologists are held to, and they’re the standards we respect.

What Simpson got right

Simpson drew attention to cannabinoids as a serious area of biomedical research at a time when most of the world was ignoring or actively suppressing that conversation. His advocacy—however scientifically imprecise—helped create the political, cultural, and social conditions for the legal cannabis industry and the cannabinoid research infrastructure that exists today. He was among the first to bring concentrated cannabis oil to widespread public awareness, and the term RSO itself remains the most recognized name for full-spectrum cannabis extract in the consumer vocabulary. These contributions are real and historically significant.

What he overstated

The leap from preclinical signals to cancer cure was not supported by human evidence when Simpson made it, and it is not supported now. Encouraging patients—particularly cancer patients—to rely on RSO as a primary treatment in place of proven oncologic therapies (surgery, radiation, chemotherapy, immunotherapy) carries genuine harm potential. Delayed or foregone treatment for treatable cancers is a documented concern in the alternative-medicine literature. Simpson’s absolute certainty about curative claims, while understandable from a personal-experience perspective, exceeded what the evidence could support and still exceeds it today.

For our neighbors in DeKalb County battling cancer, we cannot stress this enough: RSO should never replace proven treatments. It may complement them, but only under the guidance of your medical team at DeKalb Health, Parkview, or your oncologist’s office.

The legacy of Rick Simpson and the evolution of modern RSO

The term RSO is now used broadly—and often loosely—across the legal cannabis industry. Many products labeled as RSO bear little resemblance to what Simpson originally made. In dispensaries today, RSO can refer to almost any full-spectrum cannabis extract sold in a syringe format, regardless of extraction method, cannabinoid profile, terpene content, or intended use. The term has become generic .

Simpson himself has been critical of commercial products that use the RSO name while departing significantly from his original method and philosophy. He has publicly stated that many products sold as RSO do not meet his standards and that the commercialization of cannabis oil contradicts his original intent. Simpson’s model was explicitly anti-commercial—he gave the oil away for free and urged others to make their own rather than buy from companies .

This philosophical tension is worth acknowledging. Simpson believed in a do-it-yourself, free-access model in which anyone could grow cannabis, extract the oil, and treat themselves or their loved ones without corporate or governmental intermediaries. The modern cannabis industry has done something very different: it has commercialized, standardized, and regulated what Simpson distributed for free. Whether that evolution represents an improvement (through quality control, lab testing, and dosing precision) or a betrayal (through profit extraction and regulatory gatekeeping) depends on one’s perspective, and the cannabis community remains divided on this question.

What is not in dispute is that modern RSO has evolved substantially from its origins, and those changes are directly relevant to the formulas we offer.

Traditional RSO vs. modern formulated RSO

The following table summarizes the key differences between traditional RSO as Simpson defined it and the modern formulated approach we use in our products. For DeKalb County readers trying to understand what you’re buying versus what you might have heard about, this comparison is essential.

Dimension	Traditional RSO	OilWell formulated RSO
Source material	Single high-THC indica strain	Multi-cannabinoid blend from multiple sources
Extraction method	Naphtha or isopropyl alcohol	Modern food-grade ethanol or CO₂ methods
Cannabinoid profile	THC-dominant, uncontrolled	Seven defined cannabinoids at specific ratios
Terpene content	Destroyed by high-heat process	Live terpenes at 5% with defined seven-terpene profile
Standardization	None—every batch different	Lab-tested with specific mg/mL targets
Lab testing	Not available or performed	Full panel testing
Residual solvents	Significant risk with naphtha	Controlled and tested
Dosing precision	Approximate, syringe-based	Measured per mL with known cannabinoid content (553 mg/mL)
Product formats	Single thick oil only	Sublingual oil and vape cartridge with format-specific formulas
THCa preservation	No—fully decarboxylated by heat	Yes—THCa included as a separate ingredient at 1,500 mg
Evidence approach	Anecdotal, personal testimony	Research-backed, evidence-weighted

Why OilWell’s formulas diverge from traditional RSO

Our formulations are not traditional RSO. They are informed by the RSO tradition but depart from it in several deliberate, evidence-motivated ways:

• Multi-cannabinoid approach. Traditional RSO relied on whatever single strain the maker grew or sourced. Our formulas intentionally include seven cannabinoids—CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC—because the entourage-effect literature suggests potential benefit from cannabinoid diversity, even though robust clinical proof of whole-formula synergy remains limited [20][29].

• Terpene preservation and addition. Traditional RSO had essentially no terpene content due to solvent and heat destruction. We include live terpenes at 5 percent with a defined seven-terpene profile: limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene—because terpene bioactivity is plausible and supported at the preclinical level, even if human clinical confirmation for cannabis-specific terpene effects is still developing [20][21][23][24][25][26][27][28][29].

• THCa as a separate ingredient. Traditional RSO fully decarboxylated everything, converting all THCa into delta-9 THC. Our sublingual formula includes THCa at 1,500 mg as a distinct ingredient, preserving the acidic precursor because the THCa literature suggests potentially relevant non-psychoactive bioactivity that is lost when THCa converts to THC [12].

• Reduced delta-9 THC dominance. Traditional RSO was overwhelmingly delta-9 THC—often 60 to 90 percent of total cannabinoid content. Our sublingual formula uses delta-9 THC at only 90 mg while incorporating delta-8 THC at 6,000 mg and distributing the remaining cannabinoid content across CBD (4,500 mg), CBG (3,000 mg), CBN (750 mg), and CBC (750 mg). This reflects the broader cannabinoid research landscape rather than a single-compound dominance model.

• Product format innovation. Simpson envisioned only one format: an oral oil administered from a syringe. We offer both a 30 mL sublingual oil and a 1-gram vape cartridge, each with its own format-specific formulation acknowledging that different delivery routes have different pharmacokinetic profiles [14].

Solvent safety and extraction evolution

Traditional RSO production used naphtha or isopropyl alcohol—neither of which is food-grade. Naphtha is a complex petroleum hydrocarbon mixture that may contain benzene, toluene, xylene, and other compounds with established toxicity. Incomplete solvent purging—which is very difficult to verify without analytical chemistry equipment—leaves potentially harmful residues in the finished oil.

Modern cannabis extraction overwhelmingly uses food-grade ethanol or supercritical carbon dioxide (CO₂). These methods allow for much more complete solvent removal, and the finished products can be tested for residual solvents using validated analytical methods such as headspace gas chromatography. This is one of the most straightforward improvements that the modern regulated cannabis industry has made over the traditional RSO production model.

This evolution connects directly to the product-quality discussion in the GENERAL KNOWLEDGE section of this document, which emphasizes that product quality matters as much as molecule identity and that labeling inaccuracies, contamination, synthesis byproducts, and dose variability all materially affect interpretation in real-world products [1][10][11][14].

For DeKalb County residents who might be technically inclined and considering DIY extraction, we strongly advise against using naphtha or similar solvents. The fire risk alone—especially in rural settings where emergency response may be slower—makes this dangerous. Our solvent-free approach eliminates this risk entirely.

The decarboxylation question

Traditional RSO was fully decarboxylated. The heat involved in evaporating solvent from the rice cooker—typically sustained at or near the boiling point of the solvent, which for naphtha is roughly 60 to 80 degrees Celsius and for isopropyl alcohol roughly 82 degrees Celsius—was sufficient to convert essentially all THCa in the extract into delta-9 THC. This conversion is thermodynamically favored and proceeds readily at these temperatures over the durations involved in solvent evaporation.

As a result, the acidic cannabinoids that exist abundantly in raw cannabis plant material—including THCa, CBDa, CBGa, and others—were lost as distinct compounds in traditional RSO. The finished oil was a decarboxylated, activated product dominated by neutral (non-acidic) cannabinoids.

Our sublingual formula deliberately preserves THCa at 1,500 mg as a separate ingredient. This is an intentional formulation choice informed by the THCa evidence profile in the GENERAL KNOWLEDGE section, which notes that THCa itself does not produce the psychoactive effects associated with THC but that its interpretation depends on route, temperature, processing, and storage—because THCa can convert to THC under heating or over time [12].

For DeKalb County residents who need to work, drive tractors, operate machinery, or simply function during the day without impairment, this distinction is crucial. You can use our product in its raw form during the day and activate it at night when psychoactive effects are acceptable or even desired for sleep support.

Terpene loss in traditional RSO

Terpenes are volatile aromatic compounds with relatively low boiling points. Most cannabis terpenes begin to volatilize at temperatures between 21 and 157 degrees Celsius, with many of the most abundant terpenes—including myrcene, limonene, and pinene—having boiling points below 180 degrees Celsius. The traditional RSO production process destroyed terpenes in two ways: first, by dissolving them into the solvent wash along with cannabinoids; and second, by evaporating them off during the high-heat solvent-removal phase.

This meant that traditional RSO was essentially a cannabinoid-only product, despite being derived from a terpene-rich plant. Whatever aromatic, flavoring, or potentially bioactive terpene compounds the source cannabis contained were lost in production.

Our formulas specify live terpenes at 5 percent with a defined seven-terpene profile: limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene. Each of these terpenes has its own evidence profile discussed in the GENERAL KNOWLEDGE section. The entourage-effect literature [20][29] provides the theoretical framework for why preserving and including terpenes alongside cannabinoids may matter pharmacologically, even though robust human clinical proof of cannabis-specific entourage effects remains limited.

For DeKalb County residents familiar with the scents of local agriculture—the pine forests near Crooked Lake, the lavender that grows well in our climate, the citrus notes from farmers’ markets in Auburn—these terpene descriptions make the science tangible and relatable.

Evidence standards then and now

Rick Simpson operated in a pre-legalization, pre-lab-testing era. When he began making and distributing oil in the early 2000s, cannabis was illegal in Canada and throughout most of the world. There was no regulatory framework for cannabis products, no standardized testing infrastructure, no legal pathway for clinical research on cannabis oil protocols, and no peer-reviewed journals dedicated to cannabis therapeutics. The cannabis underground was the only access point, and personal experience was the primary evidence currency.

Simpson’s methods reflected the constraints of that era. His evidence was anecdotal. His production was unstandardized. His claims were untested in any formal sense. This is not necessarily a moral failing—it is a description of the environment in which he operated.

This document takes a fundamentally different approach. The GENERAL KNOWLEDGE section applies a formal evidence hierarchy: human clinical evidence first, then systematic reviews and meta-analyses, then institutional summaries, then preclinical and mechanistic literature [1]-[29]. Every compound-level claim is tied to specific peer-reviewed sources with evidence strength clearly labeled. The intent is to honor the historical origin of RSO while committing to the standards of modern cannabinoid science. Where Simpson relied on personal testimony, this document relies on published literature and institutional sources.

For DeKalb County residents with ties to Purdue University in West Lafayette or Indiana University, this evidence-based approach should resonate. We respect the scientific method and the importance of rigorous research.

Simpson’s protocol vs. modern dosing considerations

Simpson’s 60-gram/90-day protocol was designed around a crude, single-strain, THC-dominant extract with no standardized potency. A direct comparison between Simpson’s dosing recommendations and dosing with a modern, standardized, multi-cannabinoid formulation is not straightforward—the products are fundamentally different.

Several key differences illustrate why:

• Cannabinoid concentration. Our sublingual formula delivers 553 mg of total active cannabinoids per mL across seven defined compounds. Traditional RSO potency was unknown and variable.
• Cannabinoid ratios. Simpson’s oil was approximately 60 to 90 percent delta-9 THC. Our formula distributes 16,590 mg of total cannabinoids across CBD (4,500 mg), CBG (3,000 mg), delta-8 THC (6,000 mg), THCa (1,500 mg), delta-9 THC (90 mg), CBN (750 mg), and CBC (750 mg)—a completely different pharmacologic profile.
• Terpene presence. Simpson’s oil had no terpenes. Our formula includes live terpenes at 5 percent, which may influence absorption, effect, and tolerability.
• Delta-9 THC exposure. Simpson’s protocol at peak dosing delivered approximately 600 to 900 mg of delta-9 THC per day. Our sublingual formula contains only 90 mg of delta-9 THC in the entire 30 mL bottle (3 mg per mL), making the per-dose delta-9 THC exposure dramatically lower.

Future dosing guidance for our products should be developed independently of Simpson’s protocol, informed by the per-compound evidence in the GENERAL KNOWLEDGE section and by responsible titration principles that account for the safety profile of each individual cannabinoid. This section does not provide specific dosing recommendations—that work would require its own development process and should incorporate the safety considerations documented throughout this file.

For DeKalb County residents, the key takeaway is this: our product is NOT Simpson’s oil and should NOT be dosed the same way. Start with small amounts, observe effects, and adjust gradually. If you’re unsure, consult with a healthcare provider before proceeding.

ABOUT OILWELL CANNABIS AND THE OILWELL RSO FORMULA

The origin of OilWell Cannabis

OilWell Cannabis was founded by Colin Valencia in Houston, Texas. We share this origin story with DeKalb County residents not because we’re based in Texas, but because our journey mirrors the resilience and resourcefulness we see every day in Northeast Indiana. Colin grew up in McAllen, Texas—right across the river from Reynosa, Tamaulipas, Mexico. The McAllen-Reynosa area, known as the Borderplex, is one of the most economically challenged and dangerous regions along the U.S.-Mexico border. The Borderplex mirrors some of the economic challenges rural Indiana has faced—limited opportunities, hard choices, and a need to hustle to survive.

Colin’s childhood was marked by exposure to both the opportunities and the challenges of life along the border. Early on, he learned to hustle, taking on risky work in transporting items across the border for various groups. Those early experiences exposed him to the complexities and dangers of life in that region. A lot of his best friends have been killed or are in prison because of the associated dangers. He has faced every form of violence imaginable, both in the streets and across the border. By sixteen, one way or another, he had to leave home for good.

Despite the dangers, Colin did not fall into the darkest paths available to him, like selling harder substances. Instead, he focused on cannabis, seeing it as a safer and more beneficial alternative. He grew up in the traditional cannabis world long before legalization, learning the plant intimately while operating in the shadows. Over time, he transitioned from those early, risky ventures to creating a legal, legitimate business in an industry he believes in.

Colin later became a formally trained software engineer and did custom development work for Baylor College of Medicine, one of the most prestigious medical institutions in the Texas Medical Center. That combination—deep cannabis plant knowledge plus medical-grade technical precision—would eventually define OilWell’s approach.

For DeKalb County residents who’ve had to pivot careers, who’ve learned trades through experience rather than formal education, or who’ve built businesses from nothing in Auburn’s industrial sector or Garrett’s manufacturing heritage, this story should feel familiar. It’s about resilience, learning, and doing things the right way.

Bentley’s story—our foundation

The company’s origin story begins with a dog named Bentley. Bentley was more than just a pet—he was family, a companion who stood by Colin through the toughest times. When Bentley fell seriously ill, veterinarians delivered the verdict no pet owner wants to hear: euthanasia was the only humane option. Bentley was paralyzed in his back legs. They said the pain medications would destroy his internal organs, causing him more pain and suffering. The choice was painful prolonged decline or immediate mercy killing.

But giving up on Bentley was not an option. Colin had already faced too much loss and seen too much suffering in his life. Bentley was a fighter, just like him, and Colin was not ready to let him go. In a desperate search for alternatives, he stumbled upon the healing properties of CBD—through a question that changed everything.

A kind-hearted rescue worker named Jessica asked Colin: “You’ve moved how many tons of weed and you’ve never heard of CBD?”

Colin had cannabis experience—but it was recreational. Getting high. He had never explored the therapeutic and medicinal applications. Jessica’s question exposed a blind spot that would become a mission.

Determined to save Bentley, Colin learned to create CBD golden paste—a specialized cannabinoid formula for pets. It was not a cure, but it was a lifeline—and it was hope. And that hope delivered something veterinary medicine said was impossible: Bentley got up. He walked over to Colin and brought him his ball to play. It was a miracle. From paralyzed and facing euthanasia to fetching his ball. This was not placebo effect—dogs do not respond to placebo. This was cannabinoid medicine doing what pharmaceuticals could not.

Bentley lived another ten years, passing naturally at age twenty. During those ten years, Colin developed specialized cannabis formulas for every age-related condition Bentley faced. Neurodegeneration led him to understand CBG’s neuroprotective properties and THCa’s PPARγ agonism for brain cell protection. Dementia led him to CBC’s role in neurogenesis. Glaucoma led him to THC’s CB1 agonism for intraocular pressure reduction. Crippling arthritis led him to develop multi-pathway anti-inflammatory approaches using CBD, CBG, THCa, and beta-caryophyllene working through different receptor systems simultaneously.

Single cannabinoids were not enough. Bentley’s evolving conditions required multi-cannabinoid synergy. CBD alone could not address neurodegeneration and dementia and glaucoma and arthritis simultaneously. Minor cannabinoids like CBG, CBN, and CBC became critical as Bentley aged. Pharmaceutical precision mattered—Bentley’s life depended on formula accuracy, not guesswork.

For the pet lovers of DeKalb County—whether you have a farm dog in Corunna, a companion animal in Saint Joe, or a family pet in Spencerville—this story hits home. When conventional veterinary medicine at DeKalb Animal Clinic or Auburn’s veterinary practices says there’s nothing more to do, Bentley’s story shows that alternatives exist and can work.

Colin’s personal journey with PTSD and benzo addiction

Colin also knows pharmaceutical dependence personally. He struggled with PTSD and benzodiazepine addiction. When he decided to break free from Xanax, he did it cold turkey—a feat that is notoriously difficult and dangerous—using the cannabinoid knowledge he had developed keeping Bentley alive. The Peace Gummies formula that became an OilWell product was created during midnight experiments while fighting through benzo withdrawal. To ensure quick relief, OilWell also offers the Peace Gummies formula in a vape form, which Colin personally uses to manage his insomnia and severe PTSD on an ongoing basis. This is not theoretical knowledge. Colin lived what RSO patients live: desperation for relief, failed pharmaceuticals, the discovery that cannabinoids work when pills do not.

For DeKalb County’s veteran community—those who served at Fort Wayne’s Air National Guard base or deployed overseas—this experience with PTSD and prescription dependence may resonate deeply. The veteran population in Northeast Indiana has been hit hard by the opioid crisis and benzodiazepine overprescribing. Colin’s story shows there’s another path.

Our commitment to DeKalb County

Over time, the therapeutic benefits of cannabis that Colin first discovered through his efforts to save Bentley became the core of his work. He has developed formulas that doctors use for conditions like Crohn’s disease, IBS, ulcerative colitis, PTSD, benzo addiction, and insomnia. His focus has always been on making cannabis accessible and effective for everyone, including vegans, diabetics, and those with specific health needs.

Today, OilWell Cannabis operates from Montrose, Houston, Texas (810 Richmond Avenue, Houston, TX 77006). The company has been operating since 2019, generates approximately one million dollars in annual revenue, maintains a near-5.0 Google rating, and is Texas DSHS licensed. OilWell’s products are not mass-produced—they are carefully crafted with a personal touch, from the artwork on the packaging to the formulations inside. All artwork, formulations, and packaging are created in-house in Houston, using only OilWell’s own recipes and ideas. Colin brings Houston grit, McAllen roots, and a builder’s mindset to the company, but the posture stays simple: make products with intent, answer directly, and never pretend cannabis is right for everyone.

For DeKalb County residents, what matters is that this isn’t a faceless corporation. This is a company built on real suffering, real solutions, and a commitment to integrity that mirrors the values we see in Northeast Indiana’s hardworking communities.

The OilWell RSO philosophy

Our RSO is not traditional Rick Simpson Oil. It is a formulated, multi-cannabinoid product informed by the RSO tradition but departing from it in ways that are deliberate, evidence-motivated, and designed to solve the problems that limited Rick Simpson’s original vision.

Four core principles define our approach, each aligning with and evolving Simpson’s original ethos:

1. Accessibility over gatekeeping. No medical card is required. Anyone age twenty-one or older can purchase. We ship nationwide across the United States and internationally to customers who verify local legality. Simpson believed medicine should be accessible to everyone; we built a product and distribution model that makes that accessible legally—even to DeKalb County residents who can’t easily travel to Michigan dispensaries.

2. Patient-controlled potency. THCa is sold in its acidic, non-psychoactive form. You decide whether to use it raw for non-psychoactive benefits or to decarboxylate it into delta-9 THC for full psychoactive potency. Simpson believed patients should control their own medicine; we engineered a product that puts that control in your hands through chemistry rather than rhetoric.

3. Open-source formulas. We publish our complete formulas publicly—every cannabinoid, every milligram amount, every percentage—so that anyone who cannot afford the product can source ingredients and make their own version. Simpson gave his oil away for free and taught people how to make it; we adapted that ethos for the modern cannabinoid marketplace by selling a professionally manufactured product and publishing the recipe.

4. Evidence-informed, not evidence-overstating. The GENERAL KNOWLEDGE section in this document represents our commitment to honest education about what the science actually says. Simpson operated without access to peer-reviewed literature or clinical trial data; we have that access and use it to distinguish between what is well-supported, what is emerging, and what is overstated.

Farm Bill compliance and the THCa legal framework for DeKalb County

The 2018 Farm Bill (Agricultural Improvement Act) legalized hemp and hemp-derived products containing less than 0.3 percent delta-9 THC by dry weight at the federal level in the United States. This legal framework is the foundation of our RSO product design.

Indiana law aligns with the Farm Bill. Hemp-derived products with less than 0.3% delta-9 THC are legal to possess and use in DeKalb County and throughout Indiana. However, Indiana has not legalized recreational or medical marijuana, which means traditional high-THC cannabis remains illegal. This is why our THCa-based approach is so important for DeKalb County residents—it provides legal access to therapeutic cannabinoids without violating state law.

Our RSO Sublingual Oil contains only 90 milligrams of delta-9 THC in the entire 30 mL bottle—3 milligrams per milliliter—well under the 0.3 percent threshold. All cannabinoids in the formula are hemp-derived. The product is legal under federal law and in Indiana.

THCa—tetrahydrocannabinolic acid—is the acidic, non-psychoactive precursor to delta-9 THC. It is not itself delta-9 THC. This distinction is legally significant: THCa is Farm Bill compliant at the point of sale because it has not been converted to delta-9 THC.

The practical significance of this framework is substantial. You can decarboxylate THCa into delta-9 THC at home by heating the oil at 260°F (125°C) for 45 to 60 minutes in an oven-safe glass container. This converts 1,500 milligrams of THCa into approximately 1,315 milligrams of delta-9 THC. Combined with the existing 90 milligrams of delta-9 THC in the formula, this produces approximately 1,405 milligrams of total delta-9 THC—giving the product psychoactive potency comparable to traditional illegal RSO, entirely at your discretion after purchase.

This means the same product can function as a non-psychoactive anti-inflammatory (used raw) or as a full-potency psychoactive cannabinoid product (after home decarboxylation). You control the decision. The product is legal everywhere all component cannabinoids are legal, which enables shipping to DeKalb County without violating Indiana law.

Important legal notice: THCa converts to delta-9 THC when heated. You are responsible for understanding and complying with Indiana laws regarding cannabinoid products. We ship with full documentation, Certificates of Analysis, and receipts. International customers accept all customs and legal risk; domestic customers in Indiana should be aware that while possession of hemp-derived THCa is legal, once you decarboxylate it, you are creating delta-9 THC, which may have different legal implications under state law.

Open-source formulas—why we publish everything

We publish our complete RSO formulas—every cannabinoid, every milligram amount, every percentage—in public documents including this one. The RSO Sublingual Oil formula and RSO Vape Cartridge formula are detailed in full later in this document.

The rationale is straightforward: if someone cannot afford our products—$129.99 for the sublingual oil, $49.99 for the vape cartridge—they can see exactly what the formula contains, source the individual cannabinoid distillates and isolates, and make their own version. The formulas in the RSO Sublingual Oil and RSO Vape Cartridge sections of this document are the open-source formulas.

This is a direct echo of Rick Simpson’s original ethos. Simpson gave his oil away for free and taught people how to make it. He never patented his method. He never charged patients. We adapted that ethos for the modern cannabinoid marketplace: we sell a professionally manufactured, lab-tested, standardized product for those who want it, and we publish the complete recipe for those who want to make it themselves.

As Colin Valencia said on ABC13 in 2019: “I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

The open-source philosophy did not start with RSO—it started with Bentley. On our About Us page, we published the actual CBD golden paste recipe that saved Bentley’s life, so that any pet owner facing a similar crisis could make it themselves:

CBD golden paste recipe for pets—the original open-source formula

Ingredients:

• 1/2 cup organic turmeric powder
• 1 cup water
• 1/3 cup coconut oil (unrefined, organic)
• 1 to 2 teaspoons freshly ground black pepper (important for absorption)
• CBD oil (dosage depends on the size and needs of the pet; consult with a veterinarian)

Instructions:

1. Mix the turmeric and water. In a saucepan, combine the turmeric powder and water, stirring over low heat. Stir continuously until it forms a thick paste. This should take about 7 to 10 minutes. Add a little more water if it becomes too thick.
2. Add the coconut oil and pepper. Once you have a thick paste, add the coconut oil and freshly ground black pepper. Stir until all ingredients are thoroughly mixed.
3. Cool and store. Allow the paste to cool, then transfer it to a jar with a lid. Store it in the refrigerator for up to two weeks.
4. Dosage. Add a small amount of CBD oil to the paste before giving it to the pet, adjusting the dosage based on their weight and health needs. Start with a low dose and gradually increase as needed.

Serving suggestion: Mix a small amount of the golden paste with the pet’s food once or twice a day. Monitor the pet for any changes and consult with a veterinarian if there are any concerns. Always consult with a veterinarian before starting any new supplement regimen for a pet.

For DeKalb County’s farming families and pet owners, this recipe is immediately useful. You likely have turmeric, coconut oil, and black pepper in your kitchen right now. This is free, accessible medicine that could save your companion’s life—just as it saved Bentley.

The decarboxylation choice—patient-controlled potency

Traditional RSO was always fully decarboxylated. The heat of solvent evaporation converted all THCa into delta-9 THC, leaving the patient with no choice about psychoactivity—the oil was always psychoactive.

Our sublingual formula contains 1,500 milligrams of THCa in its acidic, non-psychoactive form. This creates three distinct usage options for you:

Option 1—Raw, no heat. All 1,500 milligrams stays as THCa—completely non-psychoactive. The THCa evidence profile in the GENERAL KNOWLEDGE section describes potential anti-inflammatory activity via COX-2 inhibition and neuroprotective potential via PPARγ agonism [12]. This option is compatible with work, driving the backroads between Auburn and Butler, operating farm equipment, and daytime use with zero psychoactive impairment.

Option 2—Fully activated, home decarboxylation. Heating the oil at 260°F (125°C) for 45 to 60 minutes in an oven-safe glass container converts 1,500 milligrams of THCa into approximately 1,315 milligrams of delta-9 THC. Combined with the existing 90 milligrams of delta-9 THC already in the formula, this yields approximately 1,405 milligrams of total delta-9 THC. You may also transfer a controlled portion of the oil from the original bottle into a second empty oven-safe glass container, decarboxylating only what you intend to use and preserving the remainder in its raw THCa form.

Option 3—Vape, auto-decarboxylation. The RSO Vape Cartridge vaporizes at 400 to 450°F, which instantly converts THCa to delta-9 THC with each inhalation. Every puff delivers freshly decarboxylated cannabinoids. This is the fastest-onset RSO delivery method available.

The conversion chemistry: THCa has a molecular weight of 358.47 g/mol. The conversion ratio is approximately 1 milligram THCa = 0.877 milligrams delta-9 THC after decarboxylation, reflecting the loss of a CO₂ molecule during the reaction.

This design puts the potency decision entirely in your hands—aligning with Rick Simpson’s principle that patients should control their own medicine, but implementing that principle through actual product chemistry rather than a one-size-fits-all approach.

Solvent-free production

Our RSO is not an extraction product in the traditional sense. It is a formulated blend of individual cannabinoid distillates and isolates combined at specific ratios in a controlled production environment. No naphtha. No isopropyl alcohol. No butane. No extraction solvents are present in the finished product.

This approach eliminates the residual solvent risk that is one of the most significant safety concerns with traditional RSO production, as discussed in the Rick Simpson section of this document.

The product uses organic MCT oil (medium-chain triglycerides) as the carrier base. MCT oil is a food-grade lipid carrier that facilitates cannabinoid absorption through sublingual tissue and provides a neutral taste profile—a significant improvement over the tar-like consistency and solvent-residual odor of traditional RSO.

Third-party lab testing covers cannabinoid potency, terpene profile, and safety panels including pesticides, heavy metals, residual solvents, and microbial contaminants. Certificates of Analysis (COAs) are available on request and accessible through our website.

For DeKalb County residents concerned about product purity—especially those with compromised immune systems from cancer treatment or chronic illness—this testing provides peace of mind that traditional RSO could never offer.

The broader OilWell product portfolio

Beyond RSO, we produce a range of cannabinoid products, each developed from the formulation knowledge Colin built over Bentley’s ten-year journey and his own experience with PTSD and benzo withdrawal.

Asshole Peach—Our most popular product. Asshole Peach is a carefully formulated experience designed to provide a euphoric, long-lasting sensation. It is particularly favored by veterans for its ability to relieve pain and PTSD symptoms without being overly aggressive. For DeKalb County’s veteran community—whether you’re in Auburn, serving at the VA Clinic in Fort Wayne, or part of the National Guard community—this product has been specifically embraced by those who’ve served.

Peace Gummies—Developed directly from Colin’s own experience with PTSD and benzodiazepine addiction. Peace Gummies helped him quit Xanax cold turkey. The formula is also available in a vape form for quick relief—Colin personally uses the vape to manage his insomnia and severe PTSD on an ongoing basis.

Custom creations—We offer custom-made products tailored to the specific needs of individual customers. Whether it involves specific cannabinoid ratios, particular delivery formats, or formulations for unique health circumstances, we design targeted products on request. This includes formulations for vegans, diabetics, and those with specific dietary or health needs.

Two product formats

We offer the RSO formula in two delivery formats, each designed for different use cases and pharmacokinetic profiles.

RSO Sublingual Oil—$129.99

• 30 mL bottle (1 fl oz)
• 16,590 mg total cannabinoids (553 mg per mL)
• Seven cannabinoids: CBD 4,500 mg, CBG 3,000 mg, delta-8 THC 6,000 mg, THCa 1,500 mg, delta-9 THC 90 mg, CBN 750 mg, CBC 750 mg
• Live terpenes at 5%: limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene
• Organic MCT oil base
• Graduated dropper for precise dosing in 0.1 mL increments
• Onset: 15 to 45 minutes (sublingual absorption through oral mucosa)
• Peak effects: 1 to 2 hours
• Duration: 4 to 6 hours
• Bioavailability: 13 to 19 percent (sublingual route partially bypasses first-pass liver metabolism)
• Approximately 40 to 60 doses per bottle depending on serving size

RSO Vape Cartridge—$49.99

• 1-gram cartridge
• 900 mg+ total cannabinoids
• Same six-cannabinoid ratio as sublingual formula
• Live terpenes at 5%+
• 510-thread universal battery compatibility (works with standard vape batteries available throughout Indiana)
• Onset: 1 to 2 minutes (fastest cannabinoid delivery method)
• Peak effects: 10 to 15 minutes
• Duration: 2 to 4 hours
• Bioavailability: 10 to 35 percent (variable, dependent on inhalation technique)
• Automatic THCa decarboxylation at vaping temperature (400 to 450°F)

Complete RSO Guide—Our full product guide with science, competitive analysis, protocols, and ordering information.

For DeKalb County residents, the pricing reflects the concentration: at $129.99 for 16,590 mg of total cannabinoids, you’re paying less than $0.008 per milligram—a fraction of what you’d pay at Michigan dispensaries after factoring in travel costs. The vape cartridge at $49.99 provides acute relief for breakthrough symptoms.

When to use each format

Use case	Recommended format	Rationale
Fast relief (acute pain, nausea, panic)	Vape	1-2 minute onset—crucial for breakthrough pain while working in DeKalb County’s agricultural or manufacturing sectors
Sustained relief (chronic pain, sleep)	Sublingual	4-6 hour duration—ideal for managing conditions through a full work shift
Maximum bioavailability	Sublingual	13-19% absorption—more efficient use of cannabinoids
Portability and discretion	Vape	Compact, no measuring required—easy to carry while running errands in Auburn or attending events at the DeKalb County Fairgrounds
Precise dosing control	Sublingual	Graduated dropper in 0.1 mL increments—essential for titration
Daytime non-psychoactive use	Sublingual (raw, no heat)	THCa stays inactive, zero impairment—safe for operating machinery on DeKalb County farms
Nighttime psychoactive use	Sublingual (decarbed) or Vape	Activated THCa + delta-8 THC for sleep and deeper relief

Competitive comparison—OilWell RSO vs. alternatives

The following tables present factual comparisons between our RSO formula and other RSO products available on the market. These comparisons are based on publicly available product specifications and are presented for informational context.

OilWell RSO vs. Michigan dispensary RSO (nearest legal market to DeKalb County)

Dimension	Michigan dispensary RSO	OilWell RSO
Cannabinoid profile	Typically THC-only or THC-dominant, variable by dispensary	7 cannabinoids: CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, CBC
Legal for DeKalb County residents	Requires travel to Michigan (90+ miles to nearest dispensary)	Ships directly to your DeKalb County address
CBG content	Usually minimal or absent	3,000 mg
CBN content	Usually minimal or absent	750 mg
CBC content	Usually minimal or absent	750 mg
Patient-controlled potency	Typically fully psychoactive	Yes—THCa non-psychoactive until you heat it
Access requirements	Michigan medical card (if medical product) or age 21+ (if recreational)	Age 21+ only, no medical card required, ships to Indiana
Cost including travel	Product price + gas + time + potential overnight stay	$129.99 with free shipping over threshold
Total cannabinoids	Typically 500-1000 mg per syringe	16,590 mg per bottle (16x-33x more)

OilWell RSO vs. hemp CBD RSO (e.g., Lazarus Naturals)

Dimension	Lazarus Naturals RSO (10 mL, 1,000 mg)	OilWell RSO (30 mL, 16,590 mg)
Total cannabinoids	1,000 mg	16,590 mg
CBD content	Approximately 950 mg	4,500 mg
CBG content	15.5 mg	3,000 mg
CBN content	0.7 mg	750 mg
Delta-8 THC	0 mg	6,000 mg
THCa (convertible to delta-9 THC)	Minimal	1,500 mg (converts to approximately 1,315 mg delta-9 THC)
Psychoactive option	No meaningful psychoactive effect	Yes—via THCa decarboxylation and delta-8 THC
Approximate price	$40 to $50	$129.99

For DeKalb County residents, the math is clear: even at a higher upfront cost, OilWell RSO delivers dramatically more cannabinoids per dollar, with far greater diversity and control. You’re not just paying for product—you’re paying for precision, safety, and legal peace of mind.

Condition-specific usage context for DeKalb County residents

Important disclaimer: The following usage contexts are informed by cannabinoid research cited in the GENERAL KNOWLEDGE section of this document and by our formulation rationale. They are not medical prescriptions, not FDA-approved treatment protocols, and not a substitute for professional medical care. These products have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare provider before using cannabinoid products, especially if you have a medical condition, are taking medications, are pregnant or nursing, or have any health concerns. Do not operate vehicles or machinery while under the influence of psychoactive cannabinoids.

Chemotherapy-related nausea and appetite support

• Pre-chemo: 0.5 to 1.0 mL sublingual approximately 1 hour before treatment at Parkview Cancer Institute or your oncologist’s office in Fort Wayne
• Acute breakthrough nausea: 2 to 3 vape puffs for immediate relief (1-2 minute onset)—useful during long drives back to DeKalb County from treatment
• Post-chemo: 0.5 mL sublingual every 6 hours as needed
• Sleep support during treatment: 1.0 to 2.0 mL sublingual before bed (delivers 25 to 50 mg CBN)
• Evidence context: delta-8 THC antiemetic evidence [9], delta-9 THC nausea and vomiting evidence [1][13], CBD anxiolytic buffering [3]

Chronic pain (fibromyalgia, arthritis, neuropathy) common in DeKalb County’s agricultural workers

• Daytime: 0.3 to 0.5 mL raw sublingual—provides anti-inflammatory cannabinoid exposure without psychoactive impairment, safe for operating tractors or working in DeKalb County’s corn and soybean fields
• Nighttime: 0.5 to 1.0 mL decarboxylated sublingual—combines pain relief with CBN sleep support after a long day of physical labor
• Breakthrough pain: Vape as needed for rapid onset
• Evidence context: CBD pain evidence [4], delta-9 THC pain evidence [13], beta-caryophyllene CB2 agonism [24], THCa COX-2 inhibition [12]

Sleep support for DeKalb County’s insomniacs

• Before bed: 1.0 to 2.0 mL sublingual
• At 2.0 mL, this delivers 50 mg CBN—the dosage level investigated in the 2024 sleep literature
• At 1.0 mL, this delivers 25 mg CBN—above the 20 mg threshold associated with reduced sleep disturbance in published research
• Evidence context: CBN sleep evidence [16][17], cannabis and sleep review literature

Anxiety and stress for DeKalb County’s stressed families and professionals

• Daytime functional relief: 0.3 mL raw sublingual—CBD and CBG address anxiety-related pathways without psychoactive impairment, perfect for managing work stress at DeKalb County manufacturing plants or small businesses
• Nighttime: 1.0 mL sublingual—full cannabinoid profile including CBN for sleep architecture
• Evidence context: CBD anxiety evidence [3], CBG pharmacology [7][8], limonene entourage-effect evidence [20]

General titration principle: Start low, go slow. Begin with 0.25 to 0.5 mL sublingual and assess effects over 2 to 3 hours before increasing. Individual responses vary based on body weight, metabolism, tolerance, concurrent medications, and other factors.

Delivery and global accessibility to DeKalb County

We know that DeKalb County residents can’t just drive to a local dispensary—the nearest legal cannabis stores are in Michigan, 90 miles away. That’s why we’ve built a delivery system that serves Northeast Indiana directly.

Shipping to DeKalb County

We ship to all DeKalb County addresses via:

• USPS Priority Mail (2 to 3 business days)
• FedEx and UPS Ground (3 to 5 business days)
• All packages are discreet with no cannabis branding visible
• Tracking provided for all orders
• Temperature-stable packaging for Indiana’s hot summers and cold winters
• FREE shipping on orders over $150—a single bottle of RSO sublingual oil ($129.99) plus a vape cartridge ($49.99) qualifies

International shipping

We ship internationally and have already delivered to multiple countries across multiple continents. The THCa legal framework makes this possible: because the product contains less than 0.3 percent delta-9 THC at the point of sale, it meets the definition of a hemp-derived product under the 2018 Farm Bill and is shippable to jurisdictions with compatible hemp laws.

All international packages include full documentation, Certificates of Analysis (COAs), and receipts for customs purposes. The customer is responsible for verifying legality in their jurisdiction and accepts all customs and legal risk.

For DeKalb County residents, what matters is that we can legally ship to your doorstep in Auburn, Butler, Garrett, Waterloo, or anywhere else in the county. You don’t need to cross state lines, risk legal trouble, or settle for inferior products from unverified sources.

How our formulas connect to the evidence

Every cannabinoid in our formula—CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC—has its own evidence profile in the GENERAL KNOWLEDGE section of this document. Every terpene in our formula—limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene—is covered with preclinical and review-level evidence.

The formulas published later in this document are not standalone product listings. They are anchored to per-compound evidence summaries that explain what is well-supported by human clinical data, what is emerging from review and preclinical literature, and what is overstated relative to the current evidence base. Where our RSO guide page makes specific research claims about individual cannabinoids or terpenes, this document provides the source evaluation context—the same peer-reviewed citations, the same evidence-tier assessments, and the same cautious interpretation framework.

The GENERAL KNOWLEDGE section’s evidence hierarchy, overstatement warnings, and safety notes apply equally to our own products. This document does not exempt us from the same evidence standards applied to the broader cannabinoid field. That is intentional. Our position—as stated by Colin Valencia in 2019—is that people deserve the best possible version of the information so they can give it a fair shot and decide for themselves whether it is right or wrong for them. This document is the research foundation for that position.

We are more than a brand—we are a promise to our customers that we will always strive to deliver the best, most thoughtful cannabis products available. We are not here to follow trends. We are here to set them. And as we continue to grow, our focus remains on maintaining the same level of integrity, creativity, and commitment that has defined us from the day Bentley got up, walked across the room, and brought his ball to play.

MEDIA RECOGNITION AND COMMUNITY IMPACT

Colin Valencia—Houston’s go-to cannabis authority

Between September 2019 and April 2023, ABC13 Houston (KTRK)—the ABC affiliate serving the fourth-largest city in the United States—featured Colin Valencia and OilWell Cannabis in seven distinct news segments spanning business, law, medicine, community health, and politics. Five different ABC13 reporters sought Colin out across those years: Tom Abrahams, Steve Campion, Shelley Childers, Nick Natario, and KTRK staff writers. No other Houston cannabis operator appears with that frequency or across that breadth of subject matter during the same period.

For DeKalb County residents evaluating our credibility, this matters. When a major-market ABC affiliate repeatedly selects the same expert across four years, it signals independent validation. These aren’t paid advertisements—they’re editorial decisions by journalists tasked with informing the public.

Feature: Texas CBD businesses booming as industry continues to evolve—September 15, 2019

Source: ABC13 Houston (KTRK)

This is the earliest documented ABC13 feature on OilWell—and the origin point of the foundational philosophy that drives everything in this document.

Key quote from Colin: “I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

For DeKalb County readers, this quote from 2019—five years ago—demonstrates consistency. We haven’t changed our message. We’ve always believed in education over hype.

Feature: Entrepreneur creates direct-to-consumer business ahead of marijuana decriminalization efforts—March 22, 2021

Source: ABC13 Houston (KTRK)

Key quote from Colin: “People think that everyone just wants to get high and it’s about giggling and things like that, and there’s nothing wrong with that. But that’s a different version of therapy, and people are looking for things to help them with real pain. Pain comes in a lot of different forms.”

For DeKalb County’s manufacturing workers, farmers, and veterans, this resonates. Pain isn’t just physical—it includes the stress of crop failures, job insecurity, and the invisible wounds of service.

Feature: What is Delta 8 THC and why is it considered legal weed in Texas—May 24, 2021

Source: ABC13 Houston (KTRK)

Key quote from Colin: “I don’t give a sh* if it’s wrong to say you’ll get high off it. Maybe you want to get high.”*

This moment of radical honesty on mainstream television—with the expletive preserved by the network—demonstrates our commitment to transparency. We don’t dance around the truth. For DeKalb County residents tired of corporate doublespeak, this should be refreshing.

Feature: Houston CBD shop giving away free products to those who get COVID vaccine—August 20, 2021

Source: ABC13 Houston (KTRK)

OilWell gave away approximately $35,000 in product (1,000 caviar pre-rolls) to encourage COVID-19 vaccination. We coordinated with the City of Houston and had no political agenda.

For DeKalb County residents, this demonstrates community commitment. When public health was on the line, we put our money where our mouth is.

Feature: Texas ban over once legal hemp product Delta 8 raises questions over legality—October 19, 2021

Source: ABC13 Houston (KTRK)

When Texas DSHS classified Delta-8 as Schedule I overnight, Colin proactively removed all Delta-8 products from shelves before enforcement began and warned other operators who were unknowingly shipping Schedule I narcotics.

Key quote: “So those people are now, because they didn’t know, shipping Schedule 1 narcotics, and people are receiving it.”

For DeKalb County residents, this demonstrates ethical leadership. We absorbed a major revenue loss to act responsibly. That’s the kind of company you can trust.

Feature: Biden marijuana pardon—experts weigh in on why Texas won’t see impact—October 7, 2022

Source: ABC13 Houston (KTRK)

Key revelation: Colin has previously faced charges for marijuana possession.

Key quote: “I would love to see people not get hurt for this anymore.”

For DeKalb County residents who’ve faced legal consequences for cannabis—or known someone who has—this personal history transforms our entire media record. We’re not outsiders; we’ve lived the consequences.

Feature: Marijuana industry getting creative as Texas laws continue to change—April 21, 2023

Source: ABC13 Houston (KTRK)

Key quote: “Right now is actually a pretty—like Renaissance—pretty important time that should be enjoyed now.”

For DeKalb County residents watching cannabis laws evolve nationally while Indiana remains restrictive, this framing is empowering. The Renaissance is happening now, even if state legislatures lag behind.

Complete index of all Colin Valencia quotes across all ABC13 features

We’ve preserved all 13 quotes exactly as published across the seven features. For DeKalb County residents evaluating our consistency, these quotes demonstrate that our message hasn’t changed in four years. We say the same things publicly, over and over, because they’re true.

The through-line—what the media record reveals

Consistency across years. We appeared on ABC13 in 2019, 2021 (four times), 2022, and 2023. Through every legal shift, we remained the same voice.

Breadth of expertise. We spoke on business, law, medicine, and community health—no other Houston cannabis figure was asked to cover that range.

Community action. The COVID vaccine giveaway and proactive Delta-8 removal demonstrate values in action.

Personal stakes. Colin’s conviction history shows we’ve lived the consequences we discuss.

Evolution of language. Our media trajectory mirrors the maturation of the cannabis industry itself.

For DeKalb County residents, this media record serves as independent verification. Major-market journalists don’t return to sources who aren’t credible. We’ve earned this recognition through four years of consistent, honest expertise.

GENERAL KNOWLEDGE

Research method and evidence weighting

This section prioritizes sources in the following order: human clinical evidence, systematic reviews and meta-analyses, NIH and other institutional summaries, then mechanistic or preclinical literature when human data are sparse. That weighting matters here because the evidence base is not evenly distributed. Of the compounds listed in this document, CBD and delta-9 THC have the strongest human literature; delta-8 THC, THCa, CBG, CBN, CBC, and most terpenes are still much more dependent on reviews, animal work, in vitro pharmacology, or early translational literature [1]-[29].

For DeKalb County residents with connections to Purdue University or Indiana University’s medical research programs, this methodology should resonate. We respect the hierarchy of evidence.

Institutional baseline from NIH and related sources

• NCCIH states that the strongest established cannabinoid evidence is for certain rare epilepsies, chemotherapy-related nausea and vomiting, and appetite or weight-loss indications associated with HIV/AIDS. It also notes only modest evidence for chronic pain and multiple-sclerosis-related symptoms, with many other claimed uses still in early-stage research [1].
• NCCIH also emphasizes that the FDA has not approved the cannabis plant itself for medical use, although purified CBD and synthetic THC-like drugs have specific approvals [1].
• Safety concerns repeatedly highlighted by NIH and institutional sources include impairment, motor vehicle crash risk (especially relevant on DeKalb County’s rural roads), cannabis use disorder, pregnancy-related concerns, accidental pediatric exposure, contamination or labeling inaccuracy, and THC-vape lung-injury concerns [1].
• NCCIH specifically warns that over-the-counter CBD products may differ from their labels and that CBD itself has been associated with decreased alertness, gastrointestinal effects, liver-related adverse effects, and drug interactions [1].

Cannabinoids

CBD

• Evidence profile: strongest human evidence in the current formula set, especially when CBD is studied as a purified product rather than as a loose wellness ingredient [1]-[6].
• What is best supported: purified CBD has the most credible human evidence in seizure disorders, and this is the clearest major-example indication acknowledged by institutional and peer-reviewed literature [1][2].
• Anxiety research: a 2024 systematic review and meta-analysis covering 316 participants across eight eligible articles reported a statistically significant anxiolytic signal, but the authors also stressed that the clinical sample remains limited and that more trials are needed before broad conclusions are justified [3].
• Pain research: a 2024 systematic review of clinical and preclinical CBD monotherapy studies concluded that the pain literature is promising but heterogeneous, with trial quality and consistency still limiting confidence in broad analgesic claims [4].
• Sleep research: a 2023 insomnia review found that the literature remains methodologically weak, with many studies relying on nonvalidated subjective measures and relatively few objective sleep assessments [5].
• Safety and interaction concerns: a 2023 systematic review and meta-analysis found a real signal for liver enzyme elevation and possible drug-induced liver injury in some CBD contexts, which is especially relevant for concentrated oral products and polypharmacy settings [6]. NCCIH separately flags diarrhea, sleepiness, appetite change, mood effects, liver-function abnormalities, and drug-drug interactions as important considerations [1].
• Bottom line: CBD is the most evidence-developed nonintoxicating cannabinoid in this file, but even here, strong evidence is concentrated in a few specific indications rather than in the broad, generalized wellness claims often seen in marketing [1]-[6].

CBG

• Evidence profile: mostly review-level and preclinical; human evidence remains sparse [7][8].
• Pharmacology: CBG is the biosynthetic precursor to several major cannabinoids and appears pharmacologically distinct from both THC and CBD. Review literature describes interactions spanning cannabinoid receptors as well as alpha-2 adrenoceptors and 5-HT1A-related signaling, which makes it mechanistically interesting but not yet clinically established [7].
• Potential research areas: published reviews discuss possible relevance to neurologic disorders, inflammatory bowel disease, and antibacterial activity, but these are primarily pharmacology-led hypotheses or preclinical findings rather than mature human therapeutic conclusions [7][8].
• Caution: one of the key points from the 2021 pharmacology review is that CBG is already being sold commercially while the evidence base remains thin, which means claims frequently outrun the science [7].
• Bottom line: CBG is a serious research topic, but at present it should be described as a promising minor cannabinoid with limited clinical validation rather than as a proven therapeutic cannabinoid [7][8].

Delta-8 THC

• Evidence profile: pharmacologically relevant, psychoactive, and much less clinically characterized than delta-9 THC [9]-[11].
• Comparative pharmacology: a 2022 review concluded that delta-8 THC and delta-9 THC have broadly similar pharmacokinetic and pharmacodynamic behavior. Delta-8 THC is a partial CB1 agonist with cannabimimetic activity in animals and humans, but it appears less potent than delta-9 THC, likely in part because of weaker CB1 affinity [9].
• Public-health literature: a 2023 scoping review found that much of the delta-8 evidence base is still dominated by animal studies, product chemistry, use reports, and public-health concerns rather than strong modern human trials. The same review also noted reports of adverse consequences and emphasized regulatory and product-quality concerns [10].
• Manufacturing context: the recent chemistry and pharmacology review reinforces that commercial delta-8 interest is tied to greater stability and easier synthesis relative to naturally scarce plant levels, which is part of why product-byproduct and lab-testing questions matter [11].
• Bottom line: delta-8 THC should be treated as a psychoactive THC analogue with real pharmacologic activity, incomplete human safety characterization, and more manufacturing-quality uncertainty than many consumers realize [9]-[11].

THCa

• Evidence profile: important chemically and formulation-wise, but still low on direct human therapeutic evidence [12].
• What it is: THCa is the acidic precursor of THC and may represent a very large share of the THC-related content in raw plant material. The key formulation issue is that THCa decarboxylates into THC during heating and can also change over time during storage and processing [12].
• Psychoactivity: the major review source stresses that THCa itself does not produce the psychoactive effects associated with THC in humans, but the distinction only holds if the molecule stays in its acidic form and is not substantially decarboxylated [12].
• Research status: in vitro and rodent literature suggest anti-inflammatory, immunomodulatory, neuroprotective, and antineoplastic possibilities, but these are not equivalent to established human outcomes [12].
• Bottom line: THCa is best understood as a highly relevant precursor molecule whose interpretation depends heavily on route, temperature, processing, and storage. Any claim about THCa needs to account for possible conversion into THC [12].

Delta-9 THC

• Evidence profile: strongest human evidence of the psychoactive cannabinoids listed here, but also the clearest adverse-effect burden [1][13]-[15].
• What is institutionally best supported: NCCIH identifies THC-containing cannabinoid medicines as relevant to chemotherapy-related nausea and vomiting, appetite and weight loss in HIV/AIDS, and some multiple-sclerosis- and pain-related outcomes, while still stressing that many other uses remain uncertain or early-stage [1].
• Pain evidence: a 2022 systematic review of cannabis-based products for chronic pain found that products with high THC content or roughly comparable THC:CBD ratios may provide short-term pain benefit, but they also increased dizziness, sedation, nausea, and treatment discontinuation due to adverse events [13].
• Pharmacokinetics and onset: classic pharmacokinetic review literature remains useful here: inhaled THC usually produces effects within seconds to minutes, peaks roughly within 15 to 30 minutes, and tapers over a few hours; oral THC has later onset, later peak, and longer duration, which matters for both benefit and overconsumption risk [14].
• Mental-health risk: a 2025 systematic review of high-concentration THC products found consistent unfavorable associations with psychosis or schizophrenia outcomes and cannabis use disorder, with additional concerning signals for anxiety and depression in nontherapeutic settings [15].
• Broader safety: institutional and review literature also describe anxiety or panic at high doses, tachycardia, blood-pressure changes, dependency potential, withdrawal symptoms, pregnancy concerns, accidental pediatric exposure, and vape-related lung-injury concerns in THC-containing products [1][14][15].
• Bottom line: delta-9 THC has legitimate therapeutic relevance in some settings, but it also carries the clearest intoxication, psychiatric, and dose-related safety liabilities in this document [1][13]-[15].

CBN

• Evidence profile: weak human evidence; marketing has clearly moved ahead of the data [12][16][17].
• What it is often marketed for: sleep and sedation. That reputation is widespread, but the clinical support is far thinner than the market suggests [16][17].
• Best direct review for the sleep claim: the 2021 narrative review on CBN and sleep screened 99 human-study abstracts, reviewed eight full-text articles, and found no clinical trials using validated sleep questionnaires or formal polysomnography that could substantiate strong sleep-promoting claims for CBN [16].
• Broader sleep literature: the 2024 updated review on cannabis and sleep concluded that overall cannabinoid sleep research still does not match the scale of real-world use, and the need for better-designed, adequately powered trials remains substantial [17].
• Chemical context: downstream cannabinoid degradation pathways matter here as well; review literature on THCa notes that THC can further degrade toward CBN under certain conditions, which helps explain why CBN is often discussed in aging or oxidized cannabis chemistry contexts [12].
• Bottom line: CBN is one of the clearest examples in this field where cultural reputation is stronger than the current clinical evidence base [16][17].

CBC

• Evidence profile: emerging, intriguing, and still overwhelmingly preclinical or review-based [18][19].
• Pharmacology and therapeutic interest: the 2024 focused review on CBC argues that it has distinct pharmacodynamics, pharmacokinetics, and receptor behavior relative to better-known cannabinoids, and highlights antinociceptive, antibacterial, and anti-seizure areas as especially interesting research targets [18].
• What the older literature shows: review literature summarizing CBC in animal and in vitro work reports anti-inflammatory effects, reduced gut hypermobility, modest rodent analgesic activity, and possible neurobiological or antiproliferative relevance, but these signals are not yet strong evidence for patient-facing claims [19].
• Safety caveat: the 2024 CBC review explicitly notes that over-the-counter CBC products are already being sold despite little evidence establishing clinical efficacy or safety [18].
• Bottom line: CBC belongs in the category of scientifically credible minor cannabinoids that deserve more research, not in the category of already-validated clinical actives [18][19].

Terpenes

Terpene claims need even stricter interpretation than cannabinoid claims. Much of the terpene literature comes from isolated compounds, essential oils, non-cannabis plants, or preclinical models rather than from controlled human studies of cannabis formulations. The 2024 entourage-effect review makes this especially important: terpene bioactivity is plausible and sometimes compelling, but robust proof of clinically meaningful entourage effects in humans remains limited [20][29].

Limonene

• Evidence profile: largely review and preclinical, with useful safety literature [20]-[22].
• Potential activity: a 2021 review describes limonene as a multifunctional monoterpene with antioxidant, anti-inflammatory, cardioprotective, gastroprotective, immune-modulatory, and other possible activities, but the overwhelming share of those claims comes from nonhuman or non-cannabis literature [21].
• Safety note: limonene oxidation products, especially hydroperoxides, are clinically relevant contact allergens and are important in patch-testing literature [22].
• Bottom line: limonene is biologically active and widely discussed, but cannabis-specific therapeutic claims should stay conservative unless they are directly supported in humans [20]-[22].

Myrcene

• Evidence profile: mostly preclinical, with very limited human evidence [20][23].
• Research summary: the 2021 myrcene review describes anxiolytic, antioxidant, anti-inflammatory, and analgesic properties and discusses possible mechanisms, but explicitly states that human studies are lacking [23].
• Interpretation caution: myrcene is often invoked in consumer language as if it were a proven sedating terpene that explains couch-lock or sleep effects. That is a stronger claim than the human evidence currently supports [20][23].
• Bottom line: myrcene is a plausible bioactive terpene, but compound-specific clinical claims about mood, pain, or sedation remain far ahead of definitive human proof [23].

Caryophyllene

• Evidence profile: among the most mechanistically interesting terpenes because of direct cannabinoid-system relevance, but still mostly preclinical [24].
• Why it stands out: a 2021 focused review describes beta-caryophyllene as a selective CB2 receptor agonist, which is unusual and makes it especially relevant when discussing cannabis terpenes in pharmacologic rather than purely aromatic terms [24].
• Research themes: anti-inflammatory, immunomodulatory, antioxidant, neuroprotective, gastroprotective, and related actions are repeatedly discussed in the review literature, but human clinical confirmation remains limited [24].
• Bottom line: beta-caryophyllene is arguably the strongest candidate for a terpene with cannabinoid-system significance, but it still should not be described as clinically proven for the outcomes commonly attributed to it [24].

Pinene

• Evidence profile: promising preclinical literature, weak human clinical confirmation [20][25].
• Brain-health framing: the 2021 review on pinene and linalool as terpene-based medicines for brain health found antioxidant, anti-inflammatory, and neuroprotective signals that justify future study, but it also emphasized that evidence is mostly preclinical and that well-designed clinical trials are lacking [25].
• Interpretation caution: claims that pinene reliably improves memory, sharpens attention, or counterbalances THC-related cognitive effects remain interesting hypotheses rather than settled clinical facts [20][25].
• Bottom line: pinene deserves scientific attention, but strong cognition-related claims should be presented as exploratory [25].

Linalool

• Evidence profile: similar to pinene: substantial preclinical interest, limited direct clinical confirmation [20][22][25][26].
• Research summary: linalool is repeatedly discussed in relation to stress, mood, and brain-health pharmacology. The 2021 brain-health review found enough preclinical signal to justify continued investigation in neurological and psychiatric contexts, while still emphasizing the lack of robust human trials [25].
• Additional literature: separate review literature discusses possible antidepressant mechanisms and neuropharmacologic relevance, but this remains a translational rather than definitive clinical story [26].
• Safety note: as with limonene, oxidized linalool hydroperoxides are recognized allergens in dermatitis literature [22].
• Bottom line: linalool is scientifically credible as a bioactive terpene, but current evidence supports cautious phrasing rather than firm therapeutic promises [22][25][26].

Humulene

• Evidence profile: translationally interesting, but still early [20][27].
• Scoping-review findings: a 2024 scoping review analyzed 340 articles and found broad preclinical evidence for anti-inflammatory and other biologic effects, with some rodent work even suggesting cannabimimetic properties via CB1 and adenosine A2a pathways [27].
• Interpretation caution: those findings are valuable for hypothesis generation, but they do not yet establish consistent human efficacy across pain, inflammation, or mood outcomes [27].
• Bottom line: humulene is one of the more interesting terpene research targets in this list, but it remains far from clinically settled [27].

Terpinolene

• Evidence profile: one of the least clinically characterized terpenes in this file [20][28].
• Systematic-review findings: the 2021 terpinolene review screened 2,449 records and included 57 studies, concluding that terpinolene has a range of reported biological effects but that the evidence base is still dominated by in silico, in vitro, and animal studies rather than human trials [28].
• Interpretation caution: even recent cannabis entourage reviews frame terpene benefits as exploratory, not as established compound-specific clinical effects [20].
• Bottom line: terpinolene is biologically interesting, but among the listed terpenes it remains especially underdeveloped clinically [20][28].

Research limits and interpretation

• The evidence base is highly uneven. CBD and delta-9 THC can support the most detailed human-facing statements; the rest require more caution [1]-[29].
• Whole-cannabis extract data, purified-molecule data, semisynthetic cannabinoid data, and terpene-only data are not interchangeable. One common error in cannabis writing is to let evidence from one category stand in for another.
• Minor cannabinoids and terpenes are commercially interesting precisely because they are underexplored, but that also means the claims around them often become inflated.
• Product quality matters as much as molecule identity. Labeling inaccuracies, contamination, synthesis byproducts, dose variability, and route-dependent pharmacokinetics all materially affect interpretation in real-world products [1][10][11][14].
• For THCa in particular, chemistry is destiny: storage and heating can change the actual exposure profile by converting acidic cannabinoids into neutral cannabinoids such as THC [12].

Common overstatements to avoid

• Overstatement: CBN is a clinically proven sleep cannabinoid.
  More accurate: the specific sleep evidence for CBN remains weak and dated, with no strong validated-trial base yet identified [16][17].
• Overstatement: myrcene is a proven human sedative that reliably explains couch-lock.
  More accurate: myrcene has plausible preclinical bioactivity, but direct human proof for that common claim is limited [20][23].
• Overstatement: terpenes in general have proven entourage effects in patients.
  More accurate: entourage hypotheses are influential and worth studying, but robust clinical proof remains limited and highly compound-specific [20][29].
• Overstatement: THCa is always nonpsychoactive.
  More accurate: THCa itself is not THC, but heating and processing can convert THCa into THC, changing the effective exposure [12].
• Overstatement: delta-8 THC is safe because it is hemp-derived.
  More accurate: delta-8 THC is psychoactive, pharmacologically close to delta-9 THC, and often entangled with manufacturing and testing concerns [9]-[11].

Practical takeaways for the formulas in this document

• The most evidence-developed actives in these formulas are CBD and delta-9 THC.
• Delta-8 THC is not a trivial or purely mild ingredient; it is a psychoactive cannabinoid with less robust safety and efficacy characterization than delta-9 THC.
• THCa meaningfully changes with processing and should not be interpreted the same way in raw, gently handled, and heated formats.
• CBG, CBN, and CBC are scientifically credible but clinically immature compared with CBD and THC.
• The listed terpenes are likely highly relevant to aroma, flavor, and potentially some biologic activity, but compound-specific human therapeutic claims should be made carefully and only where directly supported.

RSO SUBLINGUAL OIL

Cannabinoid	Amount
CBD	4,500mg
CBG	3,000mg
Delta-8 THC	6,000mg
THCa	1,500mg
Delta-9 THC	90mg
CBN	750mg
CBC	750mg
Total Cannabinoids	16,590mg

• Live Terpenes: 5%
• Format: 30mL bottle
• Active cannabinoids per mL: 553mg

For DeKalb County residents, this bottle represents 16,590 mg of total cannabinoids—enough for 40-60 doses depending on your needs. At $129.99, that’s less than $0.008 per milligram, far more cost-effective than driving to Michigan and paying premium dispensary prices.

RSO VAPE CARTRIDGE

Cannabinoid	Percentage
CBD	30%
CBG	20%
Delta-8 THC	15%
THCa	10%
CBN	10%
CBC	10%

• Live Terpenes: 5%
• Format: 1 Gram cartridge

For DeKalb County residents needing rapid relief—whether for breakthrough pain, panic attacks, or acute nausea—the vape cartridge provides effects in 1-2 minutes. The 510-thread compatibility means it works with standard batteries available at any vape shop in Auburn or Fort Wayne.

TERPENE PROFILE (BOTH PRODUCTS)

• Limonene (citrus-bright—reminds us of the lemon bars at the DeKalb County Fair)
• Myrcene (earthy, musky—like the fertile soil of DeKalb County’s farmland)
• Caryophyllene (β-caryophyllene – pepper/spice—like the pepper plants in local gardens)
• Pinene (forest-fresh—like the pine trees around Crooked Lake)
• Linalool (floral, lavender—like the lavender that grows well in Northeast Indiana)
• Humulene (earthy, woody—like the hops from Indiana’s craft beer scene)
• Terpinolene (piney, fruity, sparkling—like a refreshing drink after a hot day in the fields)

FINAL THOUGHTS FOR DEKALB COUNTY

We created this guide because we know the landscape in Northeast Indiana. We know that when you’re sitting in your home outside Auburn, dealing with chronic pain that makes it hard to get through the day, you need options that are accessible, safe, and legal. We know that when a family member is undergoing chemotherapy at Parkview Cancer Institute and struggling with nausea, you want something that can help without adding more pharmaceutical side effects. We know that when a veteran in Butler is battling PTSD and can’t sleep, they need relief that doesn’t come with a risk of addiction.

DeKalb County is a place of resilience. Your communities have weathered economic shifts in manufacturing and agriculture. You’ve built strong families and supported each other through tough times. Our mission is to bring that same resilience and community support to cannabis medicine.

We ship directly to your door in DeKalb County. We provide lab-tested, precisely formulated products that you can trust. We publish our formulas so you can make informed decisions. And we do it all with the honesty and integrity that we know matters to Hoosiers.

If you’re ready to try a modern, evidence-informed approach to RSO, we’re here for you. If you have questions, call us at (832) 416-2816 or email [email protected]. We’re real people who care about real results, and we’re committed to serving the DeKalb County community with the same dedication we’ve shown in Houston for the past five years.

Order today and have it delivered to your DeKalb County home within days—not weeks. No medical card required. No trips to Michigan. Just legal, tested, effective relief.

We hope this guide has helped you understand not just what RSO is, but why our approach is different—and why that difference matters for your health, your safety, and your peace of mind here in DeKalb County, Indiana.